IL1B and chronic kidney disease: Consistent with these findings, clinical observations in CKD cohorts have demonstrated a positive correlation between serum levels of IL-6/IL-1β and markers of erythrocyte membrane damage (e.g., increased osmotic fragility), as well as an inverse correlation with eryptosis (Mehta et al., 2017).